Omideon
Pre-clinicalOmideon is focused on developing novel treatments for cancer by targeting the tumour glycome. We have developed carbohydrate binding molecules (CBMs) as a new therapeutic modality for this devastating disease. Omideon’s lead candidate OMI-DG1, is a first-in-class multivalent CBM in development for ovarian cancer and colorectal cancer.
About
Omideon is focused on developing novel treatments for cancer by targeting the tumour glycome. We have developed carbohydrate binding molecules (CBMs) as a new therapeutic modality for this devastating disease. Omideon’s lead candidate OMI-DG1, is a first-in-class multivalent CBM in development for ovarian cancer and colorectal cancer.
Company Info
Contact
Sectors
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile